163 related articles for article (PubMed ID: 37638021)
1. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
McDonald PP; Leifer FG; Basso J; Lasala D; Li D; Chen KJ; Zhang J; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1231047. PubMed ID: 37638021
[TBL] [Abstract][Full Text] [Related]
2. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Chen KJ; Zhang J; LaSala D; Basso J; Chun D; Zhou Y; McDonald PP; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1185727. PubMed ID: 37441081
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
Chalmers JD; Usansky H; Rubino CM; Teper A; Fernandez C; Zou J; Mange KC
Clin Pharmacokinet; 2022 Oct; 61(10):1457-1469. PubMed ID: 35976570
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Basso J; Chen KJ; Zhou Y; Mark L; LaSala D; Dorfman A; Atalla M; Chun D; Viramontes V; Chang C; Leifer F; McDonald PP; Cipolla DC
Front Pharmacol; 2023; 14():1208780. PubMed ID: 37538173
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
[TBL] [Abstract][Full Text] [Related]
8. Simiao Yong'an decoction ameliorates murine collagen-induced arthritis by modulating neutrophil activities: An in vitro and in vivo study.
Jie SS; Sun HJ; Liu JX; Gao Y; Bai D; Zhu LL; Zhao HY; Zeng H; Ma YL
J Ethnopharmacol; 2023 Apr; 305():116119. PubMed ID: 36596398
[TBL] [Abstract][Full Text] [Related]
9. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Stump KL; Lu LD; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
Arthritis Res Ther; 2011 Apr; 13(2):R68. PubMed ID: 21510883
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
Usansky H; Yoon E; Teper A; Zou J; Fernandez C
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):832-842. PubMed ID: 35411669
[TBL] [Abstract][Full Text] [Related]
11. Isoegomaketone Alleviates the Development of Collagen Antibody-Induced Arthritis in Male Balb/c Mice.
Jin CH; So Y; Nam B; Han SN; Kim JB
Molecules; 2017 Jul; 22(7):. PubMed ID: 28753954
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic effect of Shikonin in rheumatoid arthritis by downregulating PI3K/AKT and MAPKs signaling pathways.
Liu C; He L; Wang J; Wang Q; Sun C; Li Y; Jia K; Wang J; Xu T; Ming R; Wang Q; Lin N
J Ethnopharmacol; 2020 Oct; 260():113039. PubMed ID: 32497675
[TBL] [Abstract][Full Text] [Related]
13. Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.
Kaur S; White S; Bartold M
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-12. PubMed ID: 27820156
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of lactosyl derivative Gu-4 in a collagen-induced arthritis rat model.
Fan J; Zhou H; Wang S; Wang H; Zhang Y; Guo Y; Li Q; Li Z; Zhao Z
Glycoconj J; 2012 Aug; 29(5-6):305-13. PubMed ID: 22688516
[TBL] [Abstract][Full Text] [Related]
15. Photobiomodulation ameliorates inflammatory parameters in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis.
Ryu JH; Park J; Kim BY; Kim Y; Kim NG; Shin YI
Front Immunol; 2023; 14():1122581. PubMed ID: 37063906
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive activity of 15-deoxyspergualin (15-DOS) on various models of rheumatoid arthritis.
Schorlemmer HU; Bartlett RR; Schleyerbach R; Seiler FR
Drugs Exp Clin Res; 1991; 17(10-11):471-84. PubMed ID: 1841036
[TBL] [Abstract][Full Text] [Related]
17. Crocin exerts anti-inflammatory and anti-arthritic effects on type II collagen-induced arthritis in rats.
Liu W; Sun Y; Cheng Z; Guo Y; Liu P; Wen Y
Pharm Biol; 2018 Dec; 56(1):209-216. PubMed ID: 29540097
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal peptidases and glycosidases in rheumatoid arthritis.
Sohar N; Hammer H; Sohar I
Biol Chem; 2002 May; 383(5):865-9. PubMed ID: 12108554
[TBL] [Abstract][Full Text] [Related]
19. Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-α antibody in a murine model of rheumatoid arthritis.
Katsumata K; Ishihara J; Fukunaga K; Ishihara A; Yuba E; Budina E; Hubbell JA
Arthritis Res Ther; 2019 Dec; 21(1):298. PubMed ID: 31870429
[TBL] [Abstract][Full Text] [Related]
20. Herbo-mineral formulation 'Ashwashila' attenuates rheumatoid arthritis symptoms in collagen-antibody-induced arthritis (CAIA) mice model.
Balkrishna A; Sakat SS; Joshi K; Paudel S; Joshi D; Joshi K; Ranjan R; Gupta A; Bhattacharya K; Varshney A
Sci Rep; 2019 May; 9(1):8025. PubMed ID: 31142786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
